EP2293845A1 - Depsipeptides et leur utilisation thérapeutique - Google Patents

Depsipeptides et leur utilisation thérapeutique

Info

Publication number
EP2293845A1
EP2293845A1 EP09750135A EP09750135A EP2293845A1 EP 2293845 A1 EP2293845 A1 EP 2293845A1 EP 09750135 A EP09750135 A EP 09750135A EP 09750135 A EP09750135 A EP 09750135A EP 2293845 A1 EP2293845 A1 EP 2293845A1
Authority
EP
European Patent Office
Prior art keywords
compound
mmol
solution
added
vacuo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09750135A
Other languages
German (de)
English (en)
Inventor
Stephen Joseph Shuttleworth
Franck Alexandre Silva
Cyrille Davy Tomassi
Alexander Richard Liam Cecil
Arasu Ganesan
Thomas James Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karus Therapeutics Ltd
Original Assignee
Karus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0809330A external-priority patent/GB0809330D0/en
Priority claimed from GB0809326A external-priority patent/GB0809326D0/en
Application filed by Karus Therapeutics Ltd filed Critical Karus Therapeutics Ltd
Publication of EP2293845A1 publication Critical patent/EP2293845A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un composé de formule (IX) ou (X), ainsi que les sels pharmaceutiquement acceptables de ce composé. Dans lesdites formules, X représente -C(=O)N(R10)- ou -CH(OPr3) -; R7 et R9 sont identiques ou différents et représentent un atome d'hydrogène ou une fraction de chaîne latérale d'acide aminé naturel ou non naturel; chaque R10 est identique ou différent et représente un atome d'hydrogène, un groupe alkyle C1-C6, alcényle C2-C6 ou alkynyle C2-C6; Pr1 et Pr2 sont identiques ou différents et représentent un atome d'hydrogène ou un groupe protecteur de thiol; Pr3 représente un atome d'hydrogène ou un groupe protecteur d'alcool; R1 et R5 sont identiques ou différents et représentent Y ou une fraction de chaîne latérale d'acide aminé naturel ou non naturel, à condition que R1 et R5 ne représentent pas tous deux une fraction de chaîne latérale d'acide aminé naturel ou non naturel; et Y est tel que défini dans l'invention.
EP09750135A 2008-05-22 2009-05-22 Depsipeptides et leur utilisation thérapeutique Withdrawn EP2293845A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0809330A GB0809330D0 (en) 2008-05-22 2008-05-22 Depsipeptides and their therapeutic use
GB0809326A GB0809326D0 (en) 2008-05-22 2008-05-22 Depsipeptides and their therapeutic use
US17409209P 2009-04-30 2009-04-30
PCT/GB2009/050553 WO2009141657A1 (fr) 2008-05-22 2009-05-22 Depsipeptides et leur utilisation thérapeutique

Publications (1)

Publication Number Publication Date
EP2293845A1 true EP2293845A1 (fr) 2011-03-16

Family

ID=40862855

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09750135A Withdrawn EP2293845A1 (fr) 2008-05-22 2009-05-22 Depsipeptides et leur utilisation thérapeutique

Country Status (3)

Country Link
EP (1) EP2293845A1 (fr)
GB (1) GB2460178B (fr)
WO (1) WO2009141657A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0905970D0 (en) 2009-04-06 2009-05-20 Karus Therapeutics Ltd Depsipeptides and their therapeutic use
US20130227717A1 (en) 2010-10-08 2013-08-29 Life Sciences Research Partners Vzw Hdac inhibitors to treat charcot-marie-tooth disease
JP6214397B2 (ja) * 2011-09-30 2017-10-18 国立大学法人東北大学 新規ホスファチジルイノシトール３キナーゼ阻害剤及び医薬組成物
CN102746213B (zh) * 2012-05-18 2014-06-18 潍坊博创国际生物医药研究院 肉桂酰胺类组蛋白去乙酰化酶抑制剂及其制备方法和应用
WO2015131355A1 (fr) * 2014-03-05 2015-09-11 清安医药科技武汉有限公司 Préparation du produit naturel thaïlandepsine b inhibiteur de l'histone désacétylase
JP2019052091A (ja) * 2016-01-13 2019-04-04 国立大学法人東北大学 デプシペプチド類化合物の製造中間体及びその製造方法
CN113861267B (zh) * 2021-10-25 2023-06-27 深圳湾实验室坪山生物医药研发转化中心 一种缩酯环肽类化合物lzg-pku-h及其合成方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1438966E (pt) * 1999-12-08 2007-05-31 Cyclacel Pharmaceuticals Inc Uso de depsipéptidos e seus congéneres como imunosupressores para tratamento de doenças infecciosas, como uma doença autoimune, reacções alérgicas ou doença hiperproliferativa da pele.
DE60332367D1 (de) * 2002-08-20 2010-06-10 Astellas Pharma Inc Hemmer des abbaus der extrazellulären matrix von arthrodia-knorpel
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
GB0623388D0 (en) * 2006-11-23 2007-01-03 Univ Southampton Chemical compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009141657A1 *

Also Published As

Publication number Publication date
GB2460178A (en) 2009-11-25
WO2009141657A1 (fr) 2009-11-26
GB0908868D0 (en) 2009-07-01
GB2460178B (en) 2010-08-18

Similar Documents

Publication Publication Date Title
AU2006253961B2 (en) FK 228 derivates as HDAC inhibitors
EP2089416B1 (fr) Depsipeptides et leur utilisation thérapeutique
AU2007323215B2 (en) Depsipeptides and their therapeutic use
WO2009141657A1 (fr) Depsipeptides et leur utilisation thérapeutique
EP2293846B1 (fr) Depsipeptides et leur utilisation thérapeutique
WO2009022182A1 (fr) Dérivés depsipeptidiques et leur utilisation thérapeutique
WO2010116173A1 (fr) Depsipeptides et leur utilisation thérapeutique
EP2293847B1 (fr) Depsipeptides et leur utilisation thérapeutique
MX2007015196A (es) Derivados de fk 228 como inhibidores de hdac

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20120424

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KARUS THERAPEUTICS LIMITED

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 5/11 20060101ALI20151022BHEP

Ipc: A61P 35/00 20060101AFI20151022BHEP

Ipc: C07K 5/113 20060101ALI20151022BHEP

Ipc: C07K 5/02 20060101ALI20151022BHEP

Ipc: C07K 5/107 20060101ALI20151022BHEP

Ipc: C07K 5/10 20060101ALI20151022BHEP

Ipc: C07K 5/117 20060101ALI20151022BHEP

INTG Intention to grant announced

Effective date: 20151119

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160330